Physician profile
Michelle Wallace
NPI 1699804641
$2,109.52
in general payments reported to CMS, 2019-2025
21 companies · $399 in 2025
The $399 reported for 2025 was more than what 81% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $591 · 2023: $256 · 2024: $662 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.85 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $392.74 | 2022-2025 | Wegovy, Saxenda |
| Astellas Pharma US INC | $380.37 | 2024-2025 | Veozah |
| Gynesonics, INC. | $312.80 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Vertos Medical, INC. | $198.23 | 2024 | Mild Device Kit |
| Mayne Pharma Commercial LLC | $145.90 | 2023-2025 | |
| Abbvie INC. | $116.60 | 2021-2023 | |
| Organon LLC | $96.97 | 2021-2024 | |
| Evofem Biosciences, INC. | $90.15 | 2022 | |
| Coopersurgical, INC. | $60.76 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $56.72 | 2024 | Myfembree |
| Hologic Sales and Service, LLC | $49.26 | 2024-2025 | Myosure Tissue Removal Device, Acessa Provu System |
| Ferring Pharmaceuticals INC. | $36.75 | 2021 | |
| Pfizer INC. | $29.00 | 2022 | |
| Sage Therapeutics, LLC | $23.61 | 2025 | Zurzuvae |
| Millicent US INC | $22.68 | 2025 | Intrarosa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18.11 | 2025 | Zepbound |
| Cosette Pharmaceuticals INC. | $16.18 | 2024 | Vyleesi |
| Exeltis, USA INC. | $16.11 | 2023 | Slynd |
| Shield Therapeutics INC | $15.93 | 2025 | |
| Avion Pharmaceuticals | $15.84 | 2023 | Balcoltra |
| Therapeuticsmd, INC. | $14.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.